Ferritin HIV Trimer Nanoparticles for Germinal Center Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccine technologies fail to effectively target HIV antigens to follicular dendritic cells (FDCs) in lymph nodes, leading to suboptimal humoral immune responses.
Innovation Solution
Development of glycosylated HIV antigens arranged in multivalent nanoparticle forms, such as trimer nanoparticles fused to self-assembling ferritin proteins, which facilitate mannose-binding lectin (MBL)-dependent and complement-dependent transport to germinal centers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccine technologies are used, then vaccine delivery is simplified, but targeting of HIV antigens to follicular dendritic cells (FDCs) in lymph nodes is ineffective, leading to suboptimal humoral immune responses
Solution Approach 1:
The patent employs composite nanoparticle structures combining ferritin protein cores with glycosylated HIV antigen trimers (gp120/gp41) on the surface. This composite design enables simultaneous MBL recognition (via glycans) and complement activation, achieving effective FDC targeting and robust humoral immune responses while maintaining manufacturability through recombinant protein expression systems
Solution Approach 2:
The patent introduces mannose-binding lectin (MBL) as an intermediary mechanism. The glycosylated HIV antigens on nanoparticle surfaces specifically bind to MBL, which then mediates the transport of these nanoparticles to follicular dendritic cells in lymph nodes, enabling targeted delivery that traditional vaccines cannot achieve
2Reliability
If HIV antigens are delivered without specific targeting mechanisms, then delivery process is simpler, but transport to germinal centers and activation of humoral immunity is insufficient
Solution Approach 1:
The patent modifies key parameters of the HIV antigen structure by adding glycosylation patterns (mannose residues) to the gp120/gp41 trimers. This parameter change enables specific binding to MBL, transforming the antigen from a passive delivery target to an active guided payload that efficiently reaches germinal centers through MBL-mediated transport pathways
3Reliability
If multivalent nanoparticle forms with glycosylated HIV antigens are used, then MBL-dependent and complement-dependent transport to germinal centers is enhanced, but nanoparticle production and purification becomes more complex
Solution Approach 1:
The patent utilizes the self-assembling property of ferritin proteins, which automatically form 24-subunit nanoparticle structures under physiological conditions. This self-service mechanism eliminates the need for complex assembly equipment or procedures, allowing multivalent glycosylated HIV antigen nanoparticles to form spontaneously during recombinant protein expression and purification, thereby reducing manufacturing complexity while maintaining high antigen trafficking efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances immune responses by targeting HIV antigens to lymph nodes and germinal centers, promoting stronger humoral immunity and antibody production.
Implementation Method 1
targeted to germinal centers in a complement-, mannose-binding-lectin (MBL)-, and immunogen-glycan-dependent manner
Implementation Method 2
targeted to germinal centers in a complement-, mannose-binding-lectin (MBL)-, and immunogen-glycan-dependent manner
Implementation Method 3
ferritin nanoparticle displaying an HIV trimer
Data Source
AI summary
The present invention relates to glycosylate HIV timer nanoparticles fused to self-assembling ferritin proteins which may be utilized as immunogens to enhance trafficking to lymph nodes and germinal centers and to heighten immune responses.